Another multinational pharmaceutical executive is leaving! BMS has a wave of departures after the acquisition of the new base?

", after 17 years of working with Shishi Shiguibo, Paul Biondi, Senior Vice President and Head of Strategy and Business Development, decided to leave the company in search of external opportunities. The company wishes him all the best in his new job. The company is also actively looking for a successor to Paul Biond and will announce it as appropriate. Biondlast month, according to a spokesman for the company. Biond is primarily responsible for research and development opportunities at Shishi Meishiguibao. After 13 years with the company, he was appointed head of BD in 2015, leading various licensing deals and acquisitions, including the 2018 BMS and Nektar Immune Oncology Partnership, one of Biond's largest alliances.The main content of the project is a collaboration between the two companies to develop Nektar's leading immuno-oncology project, NKTR-214, in combination with BMS's listed Opdivo treatment, and with Opdivo and BMS's other listed cancer immunotherapy heavyweight drug Yeervoy to treat more than 20 adaptations of nine tumor types. Under the terms of the agreement, BMS will pay an advance of $1.85 billion and Nektar will be eligible for an additional $1.78 billion in milestone payments.

announced the acquisition of the new base, BMS personnel changes frequentlySince January, when BMS announced its $74 billion acquisition of New Base, the company's personnel changes have been frequent.The first is that the research and development management has made a big blood change. Given the challenges faced by the combined company's oncology portfolio, the company replaced Thomas Lynch, executive vice president and chief scientific officer, with Dr. Samit Hirawat, Novarma's former head of oncology development. Hirawat will serve as chief medical officer for global drug development, one of two new core functional units in the combined business structure between New Base and BMS, BMS said in a statement.Another core unit, research and early development, is managed by Rupert Vessey, who held the same position at New Base. "Vessey will oversee the company's expanded drug discovery platform to advance science in the therapeutic field and will work closely with business development and identify external sources of innovation," BMS said.in addition to business development, Nadim Ahmed, head of hematology and oncology at New Base, will lead BMS' hematology business, and david Elkins, SYK's chief financial officer, will replace Charlie Bancroft, BMS's chief financial officer and executive vice president of global business operations, who is expected to retire next year.BMS and New Base Synthesis, a new company, are making this adjustment based on the new situation.It was also at the same time that BMS transferred Chinese mainland, its regional general manager in Hong Kong and Hong Kong, to the position of consultant to the Global Integration Planning Team. Under her leadership, BMS Opdivo (O Pharmaceuticals) became the first PD-1 to go public on Chinese mainland in May 2018 when she became general manager of BMS Chinese mainland and Hong Kong. However, it has now left BMS to join Keystone Pharmaceuticals.At the time of Mr Zhao's transfer, BMS had not announced his successor as general manager of Chinese mainland and Hong Kong, saying only that the transition period would be temporarily picked up by Marek Vasicek, BMS's general manager for Russia.It was not until the eve of the completion of the new acquisition that it was reported that BMS Chinese mainland and the new general manager of Hong Kong were Chen Siyuan, former vice president of GSK China and head of the respiratory and HIV business unit. Also announced is the news that several BMS executives will leave the company at the end of December, including Ling Yunxuan, current head of the market and strategic account team for immuno-oncology lung cancer, Chris Stijnen, current head of product strategic planning and strategy and capabilities, and Yang Shuying, current director of BMS Chinese li resources.

the flow of talents to promote the reconstruction of the pharmaceutical marketThe integration of a company's executives often leads to a series of knock-on effects that change the company's organizational structure, business plan, and even overall style. Of course, BMS's personnel changes this year are mainly aimed at matching the new company after the acquisition of the new base, while the move in China is aimed at better preempting the Chinese market.In fact, not only BMS, Sanofi, GSK, Novarma, Amgen and other multinational pharmaceutical companies have personnel changes this year, such as Sanofi CEO Bai Liyuan, Pfizer Executive Chairman Ian Read due to retirement, Sanofi Global CEO by the former Novaral CEO Han Paul, Novarma also ushered in a new president Marie France Tschudin.In China, there have also been personnel changes at these multinational pharmaceutical companies, and on March 1st Sanofi announced that Dr. Pius S. Hornstein, PhD) serves as managing director of Sanofi China and Emerging Markets Global Division in China and president of Sanofi China, while Jean-Christophe Pointeau, former president of Sanofi China, is the head of Sanofi's Europe division;It can be said that this year is a year in which the structure of multinational pharmaceutical companies adjusts more frequently!It has to be said that this has a lot to do with the development of the industry and the changes in the market environment. With the upgrading of the pharmaceutical industry, not only the Chinese market, the global pharmaceutical industry is being reconstructed, and the flow of talent is from the side influence and promote the change of the whole ecological operation rules. (New Kangjie)